Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

This study tests a combination drug approach targeting two specific brain receptors (Sigma-1 and NMDA) in people with schizophrenia who haven't responded well to at least two standard antipsychotic medications. It aims to find new ways to treat this hard-to-manage form of schizophrenia. **You may be eligible if...** - You have been diagnosed with schizophrenia (DSM-5 criteria) - You have not responded adequately to at least two different antipsychotic medications (not counting clozapine) - Your symptoms are stable but persistent, and your antipsychotic dose has been unchanged for at least 3 months - You are physically healthy with normal lab results - You can communicate effectively and complete study assessments **You may NOT be eligible if...** - You are currently being treated with clozapine - You have significant depression alongside schizophrenia - You have unstable physical health or abnormal lab results - You are pregnant Talk to your doctor to see if this trial is right for you.